Unlike the majority of biotech players, Kazia Therapeutics has emphasised diversity in its clinical trials, so as to look at the potential of its lead drug paxalisib in a range of different treatment areas.
The company currently has eight clinical trials underway, investigating the potential of the drug in various forms of brain cancer, including brain metastases, glioblastoma, and childhood brain cancer.
Kazia CEO Dr James Garner says it’s all about creating multiple shots on goal – because if you can market the drug for several different diseases it expands your commercial opportunities.
Read more here.
